Vinci SA (SQU.DE)
| Previous Close | 101.05 |
| Open | 101.35 |
| Bid | 99.08 x 0 |
| Ask | 99.24 x 0 |
| Day's Range | 98.76 - 101.35 |
| 52 Week Range | 97.74 - 120.66 |
| Volume | |
| Avg. Volume | 1,675 |
| Market Cap | 56.749B |
| Beta (5Y Monthly) | 0.92 |
| PE Ratio (TTM) | 12.06 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 4.50 (4.45%) |
| Ex-Dividend Date | Apr 23, 2024 |
| 1y Target Est | N/A |
- Simply Wall St.
Bénéteau And Two More Euronext Paris Dividend Stocks To Consider
Amidst a backdrop of general market recovery in Europe, with France's CAC 40 Index experiencing notable gains, investors are increasingly attentive to opportunities within the dividend stock arena. Given the current economic climate and market dynamics, stocks that offer consistent dividend payouts are particularly appealing for those seeking potential income alongside capital appreciation.
- Bloomberg
Hungary and Vinci Buy Budapest Airport in $4.7 Billion Deal
(Bloomberg) -- Hungary and French construction giant Vinci SA bought Budapest Airport Zrt. in a €4.3 billion ($4.7 billion) deal, handing a major asset to Prime Minister Viktor Orban who had long coveted the hub.Most Read from BloombergReal Estate Investors Are Wiped Out in Bets Fueled by Wall Street LoansBehind ‘Suicide Squad,’ the Year’s Biggest Video-Game FlopVietnam Tycoon Sentenced to Death Faces New Charges: MediaBillionaire-Friendly Modi Humbled by Indians Who Make $4 a DayThe buyers paid
- Simply Wall St.
Exploring Euronext Paris Dividend Stocks In June 2024
As of June 2024, the French market has shown some volatility with the CAC 40 Index experiencing a decline amid concerns about inflation and European Central Bank policies. This backdrop sets a cautious yet intriguing stage for investors interested in dividend stocks on Euronext Paris, which may offer potential stability and income in uncertain times. In such a market environment, a good dividend stock typically features strong fundamentals including consistent earnings, solid management, and...
